Pruritus Therapeutics Market - Growth, Trends, and Forecasts (2020 - 2025)

The Market is Segmented by Product Type (Corticosteroid, Antihistamine, Local Anesthetic, Counterirritant, Immunosuppressant, Calcineurin Inhibitors, and Others), Disease Type and Geography

Market Snapshot

Study Period: 2017-2025
Base Year: 2019
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 3.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Pruritus Therapeutics Market is expected to grow at a CAGR of 3.5% in the forecast period. Increasing prevalence of dermatological (atopic dermatitis, Urticaria, Cutaneous T-cell, psoriasis Allergic Contact Dermatitis) and systemic (Cholestasis,liver, hematological, Neurological, Oncological, Renal, and Drug-Induced) disorders contribute to market growth during the forecast period. Moreover, the introduction of novel products to cater to high unmet medical needs present currently in the market serves to be the high impact driver for the growth of the market. For instance, in April 2020, Menlo Therapeutics Inc., a biopharmaceutical company announced the top-line results from its two ongoing Phase-III clinical trials evaluating the safety and efficacy of once-daily oral serlopitant for the treatment of Pruritus associated with Prurigo nodularis. The market currently is focused on developing its product pipeline through new discoveries, one such discovery includes the identification of new T-cell subsets (Th17 & Th22). Future commercialization of such diverse pipeline products by major players of the market is expected to reinforce the growth of the market in the forecast period. Low prices, technological advancements, favorable government scenarios, partnership-driven R&D by pharmaceutical companies, and upcoming patent expiries are some of the factors propelling the market growth. However, due to lack of understanding of disease pathophysiology and a universally accepted therapy, associated side effects, and availability of advanced alternative treatment option such as phototherapy, are some of the major hindrances to the growth of the market. Nonetheless, Pruritus is one of the most common human health afflictions and is going to prompt industry players to bring forth novel drugs and is expected to generate new opportunities amid the forecast period.

Scope of the Report

Pruritus is a condition of the skin accompanied by an unpleasant and irritating itching sensation over the skin that provokes scratching. It may be caused by some chemical substances like histamine, prostaglandins, proteases, substance P, and bile salts. Sometimes accompanied by crusts, excoriations, hyperpigmentation, Lichenification, Pyoderma, increased skin creasing, and burnished nail.

By Product Type
Local Anesthetic
Calcineurin Inhibitors
Others ( Opioid Receptor Antagonists, Antidepressants and Antipruritics)
By Disease Type
Atopic Dermatitis/ Eczema
Allergic Contact Dermatitis
Cutaneous T-cell
Others ( Cholestasis, haematological, Neurological, Oncological, Renal and Drug Induced)
By Geography
North America
United States
United Kingdom
Rest of Europe
Asia Pacific
South Korea
Rest of Asia-Pacific
Middle East and Africa
South Africa
Rest of Middle East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Corticosteroid Segment is Expected to lead the Market in The Forecast Period

Based on the product type market is segmented into Corticosteroid, Antihistamine, Local Anesthetic, Counterirritant, Immunosuppressant, and Others (Opioid Receptor Antagonists, Antidepressants, and Antipruritic). Corticosteroids being the first-line drug for the treatment of Pruritus dominates the market share for the past few years. The segment is expected to record the same growth rate even in the forecast period. They are widely used to provide relief from Atopic Dermatitis or Psoriasis. The increasing demand for over the counter topical corticosteroids is expected to be a potential driver for market growth in this segment.

Kidney Disease Statistics.png

To understand key trends, Download Sample Report

North America is Expected to Dominate the Market

Globally, North America dominates the Pruritus Therapeutics Market and is anticipated to do so even in the forecast period. Regional contribution of huge market share can be attributed to the presence of Pruritus inducing climatic conditions and the growing prevalence of risk factors associated with the disease. Owing to the increasing prevalence of the targeted disease in North American countries MC2 Therapeutics, a European company in August 2020, signed a Collaboration Agreement with EPI Health, LLC for co-commercialization of its Wynzora Cream in the United States Market. In July 2020, MC2 Therapeutics received Wynzora’s United States Food and Drug Administration (USFDA) approval for the treatment of Plaque Psoriasis in adults. The upcoming launch of Wynzora cream in the American market will further project market growth. In addition, MC2 Therapeutics, currently is also working on MC2-25 PAD Cream, which is currently in phase II for the treatment of uremic pruritus. Moreover, the presence of high unmet healthcare needs (curative therapy, better safety profiles, etc) and favorable regulatory environment are some of the major factors that are expected to provide lucrative growth in the forecast period.


To understand geography trends, Download Sample Report

Competitive Landscape

The Pruritus Therapeutics Market is fragmented and competitive with large numbers of players namely Ulroac, UCB Pharma, Sanofi Aventis, Pfizer, etc. In order to maintain market dominance in this cut-throat competition era, these pharmaceutical giants have implemented key business strategies such as rigorous R&D attempts to develop novel and cost-effective therapeutics, innovative product and service launches, product expansions, and strategic collaborations. In June 2020, Cara Therapeutics, a clinical-stage biopharmaceutical company announced the successful completion of its Phase-II dose-ranging trial of oral Korsuva for moderate to severe chronic kidney disease-associated pruritus and is expected to fuel the competitiveness in the forecast period by its novel and proprietary class of product in the market.

Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevelance of Dermatological Disorders

      2. 4.2.2 Presence of High Unmet Needs

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Understanding of Disease Pathophysiology

      2. 4.3.2 Availability of Advanced Alternative Treatment Options

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Product Type

      1. 5.1.1 Corticosteroid

      2. 5.1.2 Antihistamine

      3. 5.1.3 Local Anesthetic

      4. 5.1.4 Counterirritant

      5. 5.1.5 Immunosuppressant

      6. 5.1.6 Calcineurin Inhibitors

      7. 5.1.7 Others ( Opioid Receptor Antagonists, Antidepressants and Antipruritics)

    2. 5.2 By Disease Type

      1. 5.2.1 Atopic Dermatitis/ Eczema

      2. 5.2.2 Allergic Contact Dermatitis

      3. 5.2.3 Urticaria

      4. 5.2.4 Cutaneous T-cell

      5. 5.2.5 Others ( Cholestasis, haematological, Neurological, Oncological, Renal and Drug Induced)

    3. 5.3 By Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Actavis

      2. 6.1.2 AbbVie Inc.

      3. 6.1.3 Astellas Pharma Inc

      4. 6.1.4 Cara Therapeutics

      5. 6.1.5 EPI Health, LLC

      6. 6.1.6 Gladerma Laboratories, LP.

      7. 6.1.7 Ocera Therapeutics Inc.

      8. 6.1.8 Pfizer

      9. 6.1.9 Sanofi SA

      10. 6.1.10 Trevi Therapeutics

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments.

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Pruritus Therapeutics Market market is studied from 2017 - 2025.

The Pruritus Therapeutics Market is growing at a CAGR of 3.5% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2019.

Cara Therapeutics, EPI Health, LLC , Gladerma Laboratories, LP. , Sanofi SA, AbbVie Inc. are the major companies operating in Pruritus Therapeutics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!